 Tiziana Life Sciences Ltd NASDAQ:TLSA has hailed news of an improvement in a multiple sclerosis patient being treated with intranasal foralumab in a clinical study. This second expanded access patient EA2, who has non-active secondary progressive multiple sclerosis SPMS, has shown further improvements since last reported in September last year, according to the US Food Drug Administration FDA recognised Expanded Disability Status Scale EDSS. 